Semaglutide 0.5 mg: The Second Titration Step (Weeks 5-8)
0.5 mg is the first escalation after the 0.25 mg starter — still sub-therapeutic but where most patients begin to feel real appetite suppression.
Semaglutide 0.5 mg is the standard week-5 step in the Wegovy/Ozempic titration. Doubling from the 0.25 mg starter dose doubles GLP-1 receptor activation — most patients feel appreciably more appetite suppression here than at 0.25 mg, and modest additional weight loss begins. It's still below the FDA-approved 2.4 mg therapeutic weight-loss dose, but it's the first dose where clinical effect starts to feel meaningful.
Why 0.5 mg matters in the titration
At 0.5 mg weekly, semaglutide produces appreciable GLP-1 receptor activation throughout the gut, pancreas, and CNS. Gastric emptying slows by 40-60%; central appetite signaling is more clearly suppressed; insulin secretion in response to meals increases noticeably. Patients commonly report "I forgot to eat lunch" experiences starting at this dose level — a classic sign GLP-1 is doing its job.
Per the STEP 1 trial protocol, 0.5 mg is the second 4-week titration step (weeks 5-8). After 4 weeks at 0.5 mg, the next step is 1.0 mg (weeks 9-12), then 1.7 mg, then 2.4 mg maintenance. Trimi clinicians follow this schedule by default but adjust for individual tolerability.
Side effects at the 0.5 mg step
Each titration step transiently reintroduces side effects. At 0.5 mg, the typical pattern is 5-7 days of mild nausea, fatigue, or constipation right after the dose increase, then tapering symptoms over weeks 5-7. Severe side effects warrant either holding at 0.5 mg longer before next escalation, or dropping back to 0.25 mg for a slower second attempt.
Trimi 0.5 mg protocol
- • Continue same weekly injection day from 0.25 mg starter
- • Expect transient symptom flare for 5-7 days post-increase
- • Hydration + ~30g protein per meal still important
- • Plan 4 weeks at 0.5 mg before considering escalation to 1.0 mg
- • If patient is highly responsive, can hold at 0.5 mg longer
Continue semaglutide titration with Trimi
$99/month annual plan, flat across all doses. Same active ingredient as Wegovy + Ozempic.
Start your visitFAQs
When do I escalate to semaglutide 0.5 mg?
Week 5, per the standard Wegovy/Ozempic titration. After 4 weeks at 0.25 mg starter dose, clinicians typically increase to 0.5 mg weekly. If you're tolerating 0.25 mg well, you can also escalate at week 4 — but holding at 0.25 mg an extra week is a common option if you had any side effects.
How much weight loss should I expect at 0.5 mg?
Modest. 0.5 mg is still below the therapeutic weight-management dose. STEP 1 trial protocol (NEJM 2021) shows mean weight loss accelerating once patients reach 1.0 mg and above. Most patients on 0.5 mg for weeks 5-8 see an additional 2-4 lbs of loss on top of any loss from the 0.25 mg starter period.
Do side effects come back at 0.5 mg?
Often yes, mildly. Each titration step (doubling the dose) can transiently increase nausea, fatigue, or constipation for 5-7 days as the gut re-adapts. By week 7-8 most patients are tolerating 0.5 mg with minimal symptoms.
Can I stay at 0.5 mg as my maintenance dose?
Possible but uncommon. Patients who are highly responsive to GLP-1 (significant appetite suppression at sub-therapeutic doses) sometimes maintain at 0.5 mg. But for most patients, 0.5 mg is a transition dose — clinicians escalate to 1.0 mg at week 9. Discuss with your Trimi clinician if you'd like to hold at 0.5 mg longer.
What if I have severe nausea at 0.5 mg?
Drop back to 0.25 mg for 2 more weeks, then re-attempt 0.5 mg. Force-escalating through severe nausea increases risk of medication discontinuation and isn't worth it. Most patients tolerate 0.5 mg after a slower escalation.
Is compounded semaglutide 0.5 mg the same as Wegovy 0.5 mg?
Same active ingredient, same weekly dose. Wegovy 0.5 mg is a pre-filled pen autoinjector; compounded semaglutide via Trimi is drawn from a vial into a syringe. Onboarding includes clear instructions for drawing 0.5 mg from the vial concentration. The semaglutide molecule and dose are identical.
Related reading
Disclaimer: Informational, not medical advice. Compounded semaglutide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. Always consult a licensed clinician about dose titration. **The FDA does not review or approve any compounded medications for safety or effectiveness.